1. Home
  2. USNA vs AUTL Comparison

USNA vs AUTL Comparison

Compare USNA & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • USNA
  • AUTL
  • Stock Information
  • Founded
  • USNA 1992
  • AUTL 2014
  • Country
  • USNA United States
  • AUTL United Kingdom
  • Employees
  • USNA N/A
  • AUTL N/A
  • Industry
  • USNA Medicinal Chemicals and Botanical Products
  • AUTL Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • USNA Health Care
  • AUTL Health Care
  • Exchange
  • USNA Nasdaq
  • AUTL Nasdaq
  • Market Cap
  • USNA 565.2M
  • AUTL 625.4M
  • IPO Year
  • USNA 1996
  • AUTL 2018
  • Fundamental
  • Price
  • USNA $32.95
  • AUTL $2.47
  • Analyst Decision
  • USNA Hold
  • AUTL Strong Buy
  • Analyst Count
  • USNA 1
  • AUTL 5
  • Target Price
  • USNA $36.00
  • AUTL $9.32
  • AVG Volume (30 Days)
  • USNA 149.7K
  • AUTL 1.8M
  • Earning Date
  • USNA 07-22-2025
  • AUTL 08-07-2025
  • Dividend Yield
  • USNA N/A
  • AUTL N/A
  • EPS Growth
  • USNA N/A
  • AUTL N/A
  • EPS
  • USNA 1.82
  • AUTL N/A
  • Revenue
  • USNA $876,242,000.00
  • AUTL $9,011,000.00
  • Revenue This Year
  • USNA $13.04
  • AUTL $461.76
  • Revenue Next Year
  • USNA $7.36
  • AUTL $112.66
  • P/E Ratio
  • USNA $18.09
  • AUTL N/A
  • Revenue Growth
  • USNA N/A
  • AUTL N/A
  • 52 Week Low
  • USNA $23.10
  • AUTL $1.11
  • 52 Week High
  • USNA $48.85
  • AUTL $5.00
  • Technical
  • Relative Strength Index (RSI)
  • USNA 63.95
  • AUTL 69.22
  • Support Level
  • USNA $32.01
  • AUTL $2.24
  • Resistance Level
  • USNA $33.95
  • AUTL $2.53
  • Average True Range (ATR)
  • USNA 0.87
  • AUTL 0.13
  • MACD
  • USNA 0.15
  • AUTL -0.00
  • Stochastic Oscillator
  • USNA 76.58
  • AUTL 88.55

About USNA USANA Health Sciences Inc.

Usana Health Sciences Inc is a direct selling and direct-to-consumer nutrition, personal health and wellness company. It developed and manufactured science-based nutritional, personal care and skincare products with a focus on promoting long-term health and wellness. The company has two reportable segments: direct selling and Hiya direct-to-consumer. The direct selling segment develops and manufactures high quality, science-based nutritional, personal care and skincare products with a focus on promoting long-term health and wellness in various geographic markets that are distributed through the direct selling channel. The Hiya direct-to-consumer segment is a provider of children's health and wellness products in the U.S. Key revenue is generated from Direct selling segment.

About AUTL Autolus Therapeutics plc

Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.

Share on Social Networks: